Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 13

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 13
---
 “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus, and while we believe such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely on these statements. Forward-looking statements in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements about:

| • |     | the commercialization of our approved medicines and our product candidates, if approved; |

| • |     | our ability to obtain and maintain regulatory approval for our approved medicines and our product candidates or                                 
 any of our future product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; |

| • |     | our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future 
 collaborators;                                                                                               |

| • |     | our plans to research, develop and commercialize our product candidates, including the timing of our ongoing 
 clinical trials;                                                                                             |

| • |     | our expectations regarding the size of target patient populations for our approved medicines and our product 
 candidates, if approved for commercial use, and any additional product candidates we may develop;            |

8

| • |     | the size and growth potential of the markets for our approved medicines and our product candidates, and our 
 ability to serve those markets;                                                                             |

| • |     | the rate and degree of market acceptance of our approved medicines and our product candidates, as well as 
 third-party payor coverage and reimbursement for our approved medicines and our product candidates;       |

| • |     | our ability to attract collaborators with development, regulatory and commercialization expertise; |

| • |     | our expectations regarding our ability to obtain, maintain, enforce and defend our intellectual property 
 protection for our approved medicines and our product candidates;                                        |

| • |     | governmental, regulatory and legal developments in the United States and foreign countries; |

| • |     | the performance of our third-party collaborators, suppliers and manufacturers; |

| • |     | the success of competing therapies that are or may become available; |

| • |     | our ability to attract and retain key scientific or management personnel; |

| • |     | our